Abstract 3166
Background
Aberrations in fibroblast growth factor receptors (FGFR) are common in multiple cancers, making them highly promising therapeutic targets. Optimal application of FGFR inhibitors requires a comprehensive understanding of the prevalence and types of FGFR mutations, which may vary significantly among ethnicities. Such analysis has not been conducted in Chinese pan-cancer. This study investigated the prevalence and the distribution of FGFR aberrations in Chinese cancer patients.
Methods
We screened genomic profiling results of plasma or tissue samples from 10,582 patients spanning 16 cancer types: lung, breast, gastric, hepatobiliary, pancreatic, soft tissue sarcoma, esophageal, ovarian, colorectal, head and neck, renal, endometrial, osteogenic sarcoma, cervical, melanoma and lymphoma.
Results
Of the 10,582 patients screened, we observed 745 patients with FGFR aberrations, revealing an overall prevalence of 7.03%. Approximately, 3.78% harbored FGFR amplification, 2.73% had other mutations and 0.53% had fusions. A majority (56.78%) of patients had FGFR1 aberrations, followed by 17.72%, 14.43% and 2.82% with FGFR3, FGFR2 and FGFR4 aberrations, respectively. Furthermore, 8.46% of patients with aberrations in more than 1 FGFR gene. The most common type of aberrations was amplification (53.69%), followed by other mutations (38.79%) and fusions (5.64%). Concurrent FGFR fusion and amplification occurred in 1.88% patients. Of the 16 cancer types, except for head and neck cancer, osteogenic sarcoma, renal carcinoma, and lymphoma, all other cancer types had FGFR aberrations detected with colorectal cancer (31.03%) having the highest prevalence. Other relatively commonly affected cancers included: gastric cancer (16.78%), breast cancer (14.27%) and esophageal cancer (12.68%). FGFR1 amplification was the most common genetic alteration in CRC, breast cancer and lung cancer. FGFR2 amplification was more commonly seen in gastric cancer. Of the patients with FGFR aberrations, 57 patients, spanning 9 cancer types, had fusions. Among them, breast cancer patients are more likely to have concurrent FGFR amplification than other cancer types (p < 0.001).
Conclusions
Our study provides a comprehensive view of FGFR aberrations in Chinese cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yang Gao.
Funding
Key Research and Development Program of Hunan province (2016JC2039).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2888 - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision
Presenter: Kuiyuan Liu
Session: Poster Display session 3
Resources:
Abstract
3607 - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging
Presenter: Meng Yun Qiang
Session: Poster Display session 3
Resources:
Abstract
5848 - Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses
Presenter: Chihiro Fushimi
Session: Poster Display session 3
Resources:
Abstract
4484 - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Presenter: Russell Madison
Session: Poster Display session 3
Resources:
Abstract
5753 - Trastuzumab plus docetaxel in patients with advanced HER2–positive salivary duct carcinoma: Exploratory biomarker analyses
Presenter: Hideaki Takahashi
Session: Poster Display session 3
Resources:
Abstract
3373 - Development and characterization of salivary gland cancer organoid cultures
Presenter: Wim Boxtel
Session: Poster Display session 3
Resources:
Abstract
3118 - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity
Presenter: Ekaterina Alekseeva
Session: Poster Display session 3
Resources:
Abstract
4512 - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe
Presenter: Prianka Singh
Session: Poster Display session 3
Resources:
Abstract
3961 - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial
Presenter: ATUL SHARMA
Session: Poster Display session 3
Resources:
Abstract
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract